



Press release
February 5, 2016
Gothenburg

XVIVO Perfusion AB admitted to trading on Nasdaq First North Premier

As previously announced, XVIVO Perfusion AB (publ) (the "Company" or "Xvivo Perfusion") has decided to apply for listing of XVIVO Perfusion's shares on Nasdaq First North Premier as part of preparing the company for listing on the Nasdaq Stockholm's main list. Nasdaq has approved the Company's application and the first day of trading in XVIVO Perfusion's shares on Nasdaq First North Premier will be 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.

February 5, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, tel +46 31 788 2150, email: magnus.nilsson@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
The information was submitted for publication on February 5, 2016 at 4:00 p.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.